Antengene Corporation Limited 06996.HK의 지난 분기 매출 실적은 어땠나요?
Antengene Corporation Limited의 매출 추정치는 얼마인가요?
Antengene Corporation Limited의 수익 품질 점수는 얼마인가요?
Antengene Corporation Limited는 언제 수익을 보고하나요?
Antengene Corporation Limited의 예상 수익은 얼마인가요?
Antengene Corporation Limited은 수익 기대치를 충족했나요?
주요 통계
이전 종가
--
시가
--
일일 범위
-
52주 범위
-
거래량
--
평균 거래량
2.4M
EPS(TTM)
-0.40
배당수익률
--
시가총액
--
ANTENGENE-B란 무엇인가요?
Antengene Corp. Ltd. operates as a clinical-stage Asia-Pacific biopharmaceutical company. The company is headquartered in Shanghai, Shanghai and currently employs 152 full-time employees. The company went IPO on 2020-11-20. The firm is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The firm's products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The firm mainly conducts its business in Asia-Pacific.